Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma: Expansion Cohort Analysis. J of Skin 2023, 7 (2), s179. https://doi.org/10.25251/skin.7.supp.179.